Soligenix CEO to Present at BIO Investment & Growth Summit, Highlighting Rare Disease and Public Health Pipeline

Soligenix Inc. (NASDAQ: SNGX) announced that Christopher J. Schaber, Ph.D., president and chief executive officer, will deliver a corporate presentation at the BIO Investment & Growth Summit at 3 p.m. on March 2. The conference, scheduled for March 2-3 at Eden Roc Miami Beach in Miami Beach, Florida, will feature company presentations, one-on-one meetings and programming focused on growth-stage biotechnology companies. Additional information is available on the conference website. This presentation matters as it provides a platform for Soligenix to update the investment community on its progress in addressing critical healthcare gaps.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company's Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, a first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (SGX945) in Behcet’s Disease. The advancement of these therapies is significant because they target conditions with limited treatment options, potentially improving patient outcomes and quality of life.

The Public Health Solutions business segment includes development programs for RiVax(R), a ricin toxin vaccine candidate, as well as vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), a vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of these vaccine programs incorporates the use of a proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA). This government backing underscores the importance of Soligenix's work in public health preparedness, addressing biodefense and pandemic threats that have global implications for security and health. The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX. For more information on the conference, visit the event website. The presentation at the BIO Investment & Growth Summit highlights Soligenix's dual focus on rare diseases and public health, positioning the company as a key player in biotechnology with potential impacts on both niche patient populations and broader societal health challenges.